<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01710670</url>
  </required_header>
  <id_info>
    <org_study_id>EP0041</org_study_id>
    <secondary_id>2012-002591-14</secondary_id>
    <nct_id>NCT01710670</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Three-way Crossover Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects&#xD;
      of Ethanol&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saccadic Eye Movements from 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>Average values of Latency (reaction time), Saccadic Peak Velocity, and Inaccuracy (difference between stimulus angle and corresponding saccade in percentages) will be calculated for all artifact-free saccades.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smooth pursuit eye movements from 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>The time during which the eyes are in smooth pursuit of the target will be calculated for each frequency and expressed as a percentage of stimulus duration. The average percentage of smooth pursuit for all stimulus frequencies will be used as a parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>Performance will be scored after a fixed period of 3.5 minutes and reflected visuo motor control and vigilance. The average performance scores will be used in the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body sway from 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. (antero-posterior sway in mm / 2 minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scales for Mood From 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>Visual Analog Scales according to Bond and Lader</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale for alcohol intoxication From 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>The scale consists of a 10 cm line anchored on the left end by &quot;sober&quot; and on the right end by &quot;drunk.&quot; Subjects mark a point on the line that best represents their subjective state corresponding to the condition tested. The result is a distance calculated from the mark on the line.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Verbal Learning Test from 1.5 hours Post-Dose up to 6 hours Post-Dose</measure>
    <time_frame>From 1.5 hours Post-Dose up to 6 hours Post-Dose</time_frame>
    <description>Immediate recall, immediate recognition, delayed recall, and delayed recognition to evaluate memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scales for Alertness From 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>Visual Analog Scales according to Bond and Lader</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scales for Calmness From 60 minutes Pre-Dose up to 10 hours Post-Dose</measure>
    <time_frame>From 60 minutes Pre-Dose up to 10 hours Post-Dose</time_frame>
    <description>Visual Analog Scales according to Bond and Lader</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration-time curve from zero to infinity (AUC)</measure>
    <time_frame>From Pre-Dose (- 5 minutes) to 36 hours Post-Dose</time_frame>
    <description>Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification [AUC(0-t)]</measure>
    <time_frame>From Pre-Dose (- 5 minutes) to 36 hours Post-Dose</time_frame>
    <description>Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax)</measure>
    <time_frame>From Pre-Dose (- 5 minutes) to 36 hours Post-Dose</time_frame>
    <description>Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach the maximum plasma concentration (tmax)</measure>
    <time_frame>From Pre-Dose (- 5 minutes) to 36 hours Post-Dose</time_frame>
    <description>Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal disposition rate constant (λz) with the respective terminal half-life (t1/2)</measure>
    <time_frame>From Pre-Dose (- 5 minutes) to 36 hours Post-Dose</time_frame>
    <description>Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ethanol concentrations</measure>
    <time_frame>From - 30 minutes Pre-Dose to 10 hours Post-Dose</time_frame>
    <description>Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath Ethanol concentrations</measure>
    <time_frame>From - 30 minutes Pre-Dose to 10 hours Post-Dose</time_frame>
    <description>Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ethanol Dose analyzed by a model independent parameter estimate</measure>
    <time_frame>From - 30 minutes Pre-Dose to 10 hours Post-Dose</time_frame>
    <description>Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Ethanol + Brivaracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Ethanol + Brivaracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethanol Placebo + Brivaracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B: Ethanol Placebo + Brivaracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethanol + Brivaracetam Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: Ethanol + Brivaracetam Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Strength: 200 mg (4 x 50 mg)&#xD;
Form: oral tablet&#xD;
Frequency: single dose&#xD;
Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.</description>
    <arm_group_label>Ethanol + Brivaracetam</arm_group_label>
    <arm_group_label>Ethanol Placebo + Brivaracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Form: intravenous infusion&#xD;
Frequency: continuous infusion&#xD;
Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.</description>
    <arm_group_label>Ethanol + Brivaracetam</arm_group_label>
    <arm_group_label>Ethanol + Brivaracetam Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brivaracetam Placebo</intervention_name>
    <description>In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.</description>
    <arm_group_label>Ethanol + Brivaracetam Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol Placebo</intervention_name>
    <description>In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.</description>
    <arm_group_label>Ethanol Placebo + Brivaracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers with the age between 18 and 55 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has participated or is participating in any other clinical studies of&#xD;
             investigational drug or another investigational medical product within the last 3&#xD;
             months or has participated in 4 or more Investigational Medicinal Product (IMP)&#xD;
             studies within 1 year prior to screening&#xD;
&#xD;
          -  Subject is not healthy (eg, taking any drug treatments except use of Paracetamol,&#xD;
             excessive amount of alcohol, cigarettes, caffeine consumption, having a positive drug&#xD;
             / alcohol abuse, having abnormal safety parameters)&#xD;
&#xD;
          -  Subject has not been vaccinated for hepatitis&#xD;
&#xD;
          -  Subjects has consumed any grapefruits, grapefruits juice, grapefruit-containing&#xD;
             products or star fruit within 14 days prior to dosing or not able to refrain from&#xD;
             these products during the study&#xD;
&#xD;
          -  Subject has Ethanol intolerance&#xD;
&#xD;
          -  Subject has a known hypersensitivity to any components of the Investigational&#xD;
             Medicinal Product (IMP)&#xD;
&#xD;
          -  Subject has made a blood donation or a comparable blood loss (500 ml) within the last&#xD;
             3 months prior to screening&#xD;
&#xD;
          -  subject is an employee of the investigator or study center or subject is a first line&#xD;
             family member of an employee working in the respective study center or of the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>October 17, 2012</study_first_submitted>
  <study_first_submitted_qc>October 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2012</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brivaracetam</keyword>
  <keyword>Ethanol</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01710670
org study id: EP0041
secondary id: 2012-002591-14
nct id: NCT01710670
lead sponsor: 
has dmc: No
To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects
      of Ethanol
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Other
masking: Double (Participant, Investigator)
measure: Saccadic Eye Movements from 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: Average values of Latency (reaction time), Saccadic Peak Velocity, and Inaccuracy (difference between stimulus angle and corresponding saccade in percentages) will be calculated for all artifact-free saccades.
measure: Smooth pursuit eye movements from 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: The time during which the eyes are in smooth pursuit of the target will be calculated for each frequency and expressed as a percentage of stimulus duration. The average percentage of smooth pursuit for all stimulus frequencies will be used as a parameter.
measure: Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: Performance will be scored after a fixed period of 3.5 minutes and reflected visuo motor control and vigilance. The average performance scores will be used in the analysis.
measure: Body sway from 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. (antero-posterior sway in mm / 2 minutes)
measure: Visual Analog Scales for Mood From 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: Visual Analog Scales according to Bond and Lader
measure: Visual Analog Scale for alcohol intoxication From 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: The scale consists of a 10 cm line anchored on the left end by "sober" and on the right end by "drunk." Subjects mark a point on the line that best represents their subjective state corresponding to the condition tested. The result is a distance calculated from the mark on the line.
measure: Visual Verbal Learning Test from 1.5 hours Post-Dose up to 6 hours Post-Dose
time frame: From 1.5 hours Post-Dose up to 6 hours Post-Dose
description: Immediate recall, immediate recognition, delayed recall, and delayed recognition to evaluate memory
measure: Visual Analog Scales for Alertness From 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: Visual Analog Scales according to Bond and Lader
measure: Visual Analog Scales for Calmness From 60 minutes Pre-Dose up to 10 hours Post-Dose
time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose
description: Visual Analog Scales according to Bond and Lader
measure: The area under the plasma concentration-time curve from zero to infinity (AUC)
time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
description: Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
measure: The area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification [AUC(0-t)]
time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
description: Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
measure: The maximum plasma concentration (Cmax)
time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
description: Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
measure: The time to reach the maximum plasma concentration (tmax)
time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
description: Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
measure: The terminal disposition rate constant (λz) with the respective terminal half-life (t1/2)
time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose
description: Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.
measure: Serum Ethanol concentrations
time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
description: Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
measure: Breath Ethanol concentrations
time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
description: Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
measure: Total Ethanol Dose analyzed by a model independent parameter estimate
time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose
description: Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.
arm group label: Ethanol + Brivaracetam
arm group type: Experimental
description: Treatment A: Ethanol + Brivaracetam
arm group label: Ethanol Placebo + Brivaracetam
arm group type: Experimental
description: Treatment B: Ethanol Placebo + Brivaracetam
arm group label: Ethanol + Brivaracetam Placebo
arm group type: Experimental
description: Treatment C: Ethanol + Brivaracetam Placebo
intervention type: Drug
intervention name: Brivaracetam
description: Strength: 200 mg (4 x 50 mg)
Form: oral tablet
Frequency: single dose
Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.
arm group label: Ethanol + Brivaracetam
arm group label: Ethanol Placebo + Brivaracetam
intervention type: Other
intervention name: Ethanol
description: Form: intravenous infusion
Frequency: continuous infusion
Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.
arm group label: Ethanol + Brivaracetam
arm group label: Ethanol + Brivaracetam Placebo
intervention type: Other
intervention name: Brivaracetam Placebo
description: In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
arm group label: Ethanol + Brivaracetam Placebo
intervention type: Other
intervention name: Ethanol Placebo
description: In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
arm group label: Ethanol Placebo + Brivaracetam
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: UCB Clinical Trial Call Center
role: Study Director
affiliation: +1 877 822 9493 (UCB)
facility: 
country: Netherlands
responsible party type: Sponsor
mesh term: Ethanol
mesh term: Brivaracetam